News Articles and Montana BioScience Alliance Newsletters
The Montana Innovation Partnership at Montana State University’s TechLink Center will host “Innovate Here,” a one-day virtual conference March 7 focused on key technology industries in Montana, such as bioscience, photonics and quantum technologies.
Microbion recently announced another significant milestone in the development of its lead drug candidate, pravibismane. The U.S. FDA has granted pravibismane a second orphan drug designation for the treatment of non-tuberculous mycobacterial (NTM) infections.
In a recent dissertation by Carlos Jaser Lara de Larrea, the focus turns to practical solutions for a cleaner water future. The research, titled “Treatment of biofilms and opportunistic pathogens in simulated drinking water distribution systems using UV LEDs,” takes a straightforward approach to tackle biofilm issues in drinking water systems.
This revolutionary new immunotherapy will combine Intrommune’s disease-modifying treatment through its peanut oral mucosal immunotherapy (OMIT), with the rapid desensitization to allergens provided by Inimmune’s clinical stage proprietary immunotherapy.
Working every day with your best friend would be a dream come true for some people. Getting to work with your best friend to provide a vital service to your hometown community would make it even more special. For University of Montana alums Stacy Conrow-Ververis and Laurel Chambers that dream is a reality.
Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.
As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.
Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR
Contract Pre-solicitation for R&D that will contribute toward ARPA-H mission needs and SBIR program objectives.
Updates from product development and small business programs
View the Winter II 2024 Newsletter now!
View the Winter 2023 Newsletter now!